Key result
LMWH is recommended for initial and long-term cancer-related VTE management despite unknown optimal duration.
Why the study?
Venous thromboembolism is a common and serious complication in cancer patients with distinct risk factors and management challenges that require updated synthesis of current knowledge.
Population
Cancer patients with or at risk of venous thromboembolism
Comparison
Various anticoagulation strategies including LMWH, enoxaparin, UFH, fondaparinux, and inferior vena cava filters
Design
Literature review
Authors
Loading...
LMWH preferred for cancer VTE; leaves optimal duration open for prospective trials.
This review highlights that LMWH is the preferred anticoagulant for initial and long-term management of cancer-associated VTE, and emphasizes the use of risk assessment models like the Khorana Risk Score.
Deng et al. (2014) conducted a review in Venous thromboembolism in cancer patients. Anticoagulation was evaluated. Low molecular weight heparin is recommended for both initial and long-term management of cancer-related venous thromboembolism, though optimal duration of anticoagulation remains unknown.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: